{
    "organizations": [],
    "uuid": "068908570724e3665f66c6e84442830927792396",
    "author": "",
    "url": "https://www.reuters.com/article/brief-novelion-therapeutics-announces-co/brief-novelion-therapeutics-announces-cost-reduction-plans-capital-structure-review-idUSASB0C26K",
    "ord_in_thread": 0,
    "title": "BRIEF-Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 21 PM / Updated 11 minutes ago BRIEF-Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review Reuters Staff \nJan 24 (Reuters) - Novelion Therapeutics Inc: \n* NOVELION THERAPEUTICS ANNOUNCES COST REDUCTION PLANS AND CAPITAL STRUCTURE REVIEW \n* NOVELION THERAPEUTICS -ANNOUNCED COST REDUCTION PLANS AS IT MANAGES CASH RESOURCES, EFFECTS OF DELAY & UNCERTAINTY OF SETTLEMENT OF UNIT WITH DOJ, SEC \n* NOVELION THERAPEUTICS - IN ADDITION TO WORKFORCE AND OTHER COST REDUCTIONS, PURSUING LICENSING OPPORTUNITIES FOR ITS ZURETINOL DRUG CANDIDATE Source text for Eikon: Further company coverage:",
    "published": "2018-01-24T23:20:00.000+02:00",
    "crawled": "2018-01-24T23:39:54.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "cost",
        "reduction",
        "plan",
        "capital",
        "structure",
        "review",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "novelion",
        "therapeutic",
        "inc",
        "novelion",
        "therapeutic",
        "announces",
        "cost",
        "reduction",
        "plan",
        "capital",
        "structure",
        "review",
        "novelion",
        "therapeutic",
        "cost",
        "reduction",
        "plan",
        "manages",
        "cash",
        "resource",
        "effect",
        "delay",
        "uncertainty",
        "settlement",
        "unit",
        "doj",
        "sec",
        "novelion",
        "therapeutic",
        "addition",
        "workforce",
        "cost",
        "reduction",
        "pursuing",
        "licensing",
        "opportunity",
        "zuretinol",
        "drug",
        "candidate",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}